Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "Amobarbital sodium is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident." assertion.
- association label "Hypertension; toxemia; pregnancy; and hypersensitivity." assertion.
- association label ""Zafirlukast tablets are contraindicated in patients who are hypersensitive to zafirlukast or any of its inactive ingredients. Zafirlukast tablets are contraindicated in patients with hepatic impairment including hepatic cirrhosis."" assertion.
- association label "Cevimeline hydrochloride is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma." assertion.
- association label ""Active uveal inflammation. Most cases of angle-closure glaucoma without iridectomy, due to the possibility of increasing angle block. Hypersensitivity to the active or inactive ingredients."" assertion.
- association label "Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D." assertion.
- context label "adults" assertion.
- association label "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]." assertion.
- association label "In some cases, this may be justifiable–for example, escitalopram is approved for treatment of generalized anxiety disorder, but its enantiomer, citalopram, is not [15]." assertion.
- context label "adults" assertion.
- MONDO_0001942 label "generalized anxiety disorder" assertion.
- MONDO_0001942 label "generalized anxiety disorder" assertion.
- MONDO_0001942 label "generalized anxiety disorder" assertion.
- MONDO_0001942 label "generalized anxiety disorder" assertion.
- association label "Furthermore, the efficacy of trazodone in the treatment of primary insomnia or generalized anxiety disorders alone is weak, and the use of certain anti-depressants over FDA-approved benzodiazepines in anxiety disorders has been shown to be associated with a higher risk of adverse drug events [18, 32]." assertion.
- context label "adults" assertion.
- association label "Information only available from Table 3" assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "Anti-psychotics had the second highest rate of off-label prescription (28.6%)–the most common off-label use was for major depressive disorder." assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- MONDO_0024614 label "neurotic depression" assertion.
- MONDO_0024614 label "neurotic depression" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- association label "In a study published by Wilcox et al. [19], the alpha- 1 adrenergic receptor antagonist prazosin did not differ from placebo in reducing alcohol consump- tion in 36 participants." assertion.
- cohort label "Adults" assertion.
- association label "Only a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." assertion.
- context label "adults" assertion.
- association label "It has been tested in multiple clinical trials since it could be promising in AUD treatment. Topiramate decreases reinforcing effects of alcohol and craving. A meta-analysis, based on data from seven random studies (2003-2014), suggested that topiramate might have beneficial effects in AUD treatment but because of its many side effects, the use is limited. The most common side effects are cognitive dysfunction, paresthesia, and taste abnormalities. " assertion.
- DOID_1574 label "alcohol use disorder" assertion.
- DOID_1574 label "alcohol use disorder" assertion.
- DOID_1574 label "alcohol use disorder" assertion.
- DOID_1574 label "alcohol use disorder" assertion.
- association label "Studies have been conducted on both the main drugs used in alcohol dependence (NTX and ACA) and on the off-label drugs (topiramate, ondansetron, sertraline and olanzapine)." assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia. " assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia. " assertion.
- association label "Long-term prophylactic treatment relies on lithium, off-label use of valproate, and growing use of modern antipsychotics." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "While trazodone is approved for the treatment of depression, the off-label use of this medication for insomnia has surpassed its usage as an antidepressant." assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. Table 1" assertion.
- context label "children and adolescents" assertion.
- MONDO_0005379 label "Neurotic disorder" assertion.
- MONDO_0005379 label "Neurotic disorder" assertion.
- MONDO_0005379 label "Neurotic disorder" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- MONDO_0005352 label "Conduct disorder" assertion.
- MONDO_0005352 label "Conduct disorder" assertion.
- MONDO_0005352 label "Conduct disorder" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. Quetiapine was mainly prescribed for neurotic disorder or depression, while aripiprazole was prescribed most frequently for conduct disorder or neurotic disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- MONDO_0005303 label "Drug dependence" assertion.
- MONDO_0005303 label "Drug dependence" assertion.
- MONDO_0005303 label "Drug dependence" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- context label "Children" assertion.
- context label "Children" assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- context label "Children" assertion.
- cohort label "Adults" assertion.
- association label "Ketamine remains an off-label treatment for treatment-resistant depression with factors that limit widespread use including its dissociative effects and abuse potential." assertion.
- association label "This review summarize the present knowledge of IFN-β mechanism of action, the overall safety, and the short- and long-term efficacy of its use in relapsing remitting Multiple Sclerosis and clinically isolated syndromes" assertion.
- cohort label "Children and adolescents" assertion.
- association label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)" assertion.
- spi label "https://doi.org/10.12688/f1000research.51018.1" assertion.
- obesity_together_With_metabolic_abnormality label "obesity together with metabolic abnormality" assertion.
- spi label "Obesity when accompanied by metabolic abnormality is closely associated with knee osteoarthritis." assertion.
- example-obesity-together-with-metabolic-abnormality label "obesity together with metabolic abnormality" assertion.
- mystatement label "All cats are gray" assertion.
- spi label "the protein TDP-43 generally contributes to the transcription of STMN2 in human motor neurons" assertion.
- relative-neocortex-size label "Relative size of the neocortex" assertion.
- spi label "the protein TDP-43 generally contributes to the transcription of STMN2 in human motor neurons" assertion.
- automatedDiscovery label "Automated Discovery" assertion.
- digital-humanities-research label "Digital Humanities Research" assertion.
- expression-of-genes-IRX3-and-IRX5 label "expression of genes IRX3 AND IRX5" assertion.
- spi label "A regulatory element within the first intron of FTO affects IRX3 and IRX5 expression during early adipogenesis" assertion.
- spi label "The OpenBiodiv knowledge graph contains semantic triples extracted from biodiversity literature" assertion.